Jacoby, Elad http://orcid.org/0000-0003-1411-8942
Ghorashian, Sara
Vormoor, Britta
De Moerloose, Barbara
Bodmer, Nicole
Molostova, Olga
Yanir, Asaf D
Buechner, Jochen http://orcid.org/0000-0001-5848-4501
Elhasid, Ronit http://orcid.org/0000-0002-5663-6919
Bielorai, Bella
Rogosic, Srdan
Dourthe, Marie-Emilie
Maschan, Michael http://orcid.org/0000-0003-1735-0093
Rossig, Claudia
Toren, Amos
von Stackelberg, Arend
Locatelli, Franco
Bader, Peter http://orcid.org/0000-0003-4554-0265
Zimmermann, Martin
Bourquin, Jean Pierre
Baruchel, Andre http://orcid.org/0000-0003-0120-6089
Funding for this research was provided by:
Israel Cancer Association (20200081)
Article History
Received: 23 June 2021
Revised: 1 March 2022
Accepted: 11 March 2022
First Online: 25 April 2022
Competing interests
: This study was not supported by phama but by a NPO grant (ICA to Dr. Jacoby). EJ reports participation of advisory boards for Novartis and Lonza and speaker’s fee from Novartis. SG reports honoraria and conference support from Novartis. BDM reports participation of advisory boards for Novartis, NB reports speaker’s fee from Novartis. JB has received personal fees, advisory board/steering committee honoraria, and nonfinancial support from Novartis; and advisory board honoraria from Pfizer, Kite, and Janssen. MM reports speaker’s fee from Miltenyi. CR reports participation in advisory boards by Amgen, BMS, Celgene, Novartis and Pfizer. AB reports participation on advisory boards and travel from Servier, Celgene, Novartis, Jazz, AstraZeneca, and being an investigator on trials from Novartis, Kite, Celgene and Cellectis. BV, OM, AY, RE, BB, SR, ED, AT, AVS, FL, PB, and JPB report no conflict of interests.